286 / 1851
FolFox vs 5FU/CDDP
Conroy, T., Lancet Oncol. 2014 Mar;15(3):305-14
Phase III trial
267 pts – SCC: 85.8% - Stage III-IV: 61%
FolFOx RT 5FU/CDDP/RT
Grade ¾
toxicities (%)
30.6
31.3
3-yr PFS (%)
18.2
17.4
OS (%)
20.2
17.5
No difference – better tolerated?